We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Republican lawmakers are on the verge of renewing their push for medical liability
legislation, which will likely contain a provision that critics contend would
bar punitive damages against drugmakers that market dangerous products.
GenVec (GNVC) has received a $10 million one-year contract extension of its
HIV vaccine development work with the Vaccine Research Center, part of the NIH's
National Institute of Allergy and Infectious Diseases.
Cornerstone BioPharma has announced the acquisition of the Extendryl family
of products from Fleming & Company, Pharmaceuticals, which occurred Jan.
1.
Sepracor has announced the formation of a partnership with Acadia Pharmaceuticals
for development of new drug candidates targeted toward treatment of central
nervous system (CNS) disorders.
Locus Pharmaceuticals has entered into a cooperative research and development
agreement (CRADA) with the U.S. National Cancer Institute (NCI) to develop novel
anticancer therapies using Locus' proprietary, fragment-based, computational
technology.
Chronogen, a drug discovery company developing therapeutics to treat age-dependent
diseases has announced an agreement with Sosei, a leading Japanese biopharmaceutical
company focused on drug development.
A major technology alliance between Tunisia and Canada was announced during
a ceremony attended by representatives of the Tunisia Ministry of Public Health,
Jacques Saada, Canadian Minister responsible for the Francophonie, and many
distinguished guests.
Private biopharmaceutical firm Xencor and Chugai
Pharmaceutical, the fifth largest pharmaceutical company in Japan in terms of
sales, have formed a license and collaboration agreement to create monoclonal
antibodies to be used against a proprietary cancer target.